Don't miss SGLT Tools - PowerPoint slide library for SGLT2 inhibitors

Polycystic kidney disease (ADPKD)

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators.
N Engl J Med. 2017 Nov 4
Google Plus
LinkedIn

Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease

Steven Soroka, Ahsan Alam, Micheli Bevilacqua, Louis-Philippe Girard, Paul Komenda, Rolf Loertscher, Philip McFarlane, Sanjaya Pandeya, Paul Tam, Daniel G. Bichet
Can J Kidney Health Dis. 2017; 4: 2054358117695784.
Google Plus
LinkedIn

Tolvaptan in patients with autosomal dominant polycystic kidney disease

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators
N Engl J Med. 2012 Dec 20;367(25):2407-18
Google Plus
LinkedIn

Volume progression in polycystic kidney disease (CRISP)

Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP; CRISP Investigators
N Engl J Med. 2006 May 18;354(20):2122-30
Google Plus
LinkedIn

ukidneyisup